MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
Aurora Cannabis Revenue 2011-2026 | ACB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aurora Cannabis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 175 M | 221 M | 245 M | 269 M | 246 M | 55.2 M | 18.1 M | 1.44 M | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 269 M | 1.44 M | 154 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | $ 18.02 | - | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.58 | 1.18 % | $ 1.34 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
272 M | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Evolus
EOLS
|
297 M | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Tilray
TLRY
|
627 M | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Pacira BioSciences
PCRX
|
542 M | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
16.9 M | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 2.28 | -5.39 % | $ 2.83 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.07 | 0.98 % | $ 23.9 M | USA |